- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Berman named CEO of Lumisys
Lumisys president Philip Berman has added the title of CEO, assuming that post from chairman Douglas DeVivo. Berman, who came to Lumisys in November when the company acquired CompuRad, will spearhead the company's entrée into the computed
Lumisys president Philip Berman has added the title of CEO, assuming that post from chairman Douglas DeVivo. Berman, who came to Lumisys in November when the company acquired CompuRad, will spearhead the company's entrée into the computed radiography market (SCAN 5/13/98).
Berman's appointment comes soon after other management moves by the company. COO and CFO Craig Klosterman has left the company to join Informatica, a private software company. Replacing Klosterman as CFO is vice president of finance Dean MacIntosh. Also, the company has hired Duncan Moffat for the newly created post of vice president of operations.
In other Lumisys news, the company has begun a road show to commemorate the launch of its ACR-2000 desktop computed radiography unit, which Lumisys plans to sell through the same network of OEMs that market its film digitizers. Vice president of channel development and sales Scott Evers is traveling around the U.S. in a new yellow Volkswagen Beetle to demonstrate the unit to clinics, hospitals, OEMs, VARs, and systems integrators. The trip will conclude at this year's Radiological Society of North America meeting, with commercial deliveries expected to begin in early 1999.
Four Strategies to Address the Tipping Point in Radiology
January 17th 2025In order to flip the script on the impact of the radiology workforce shortage, radiology groups and practices need to make sound investments in technologies and leverage partnerships to mitigate gaps in coverage and maximize workflow efficiencies.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI-Based AI Enhance Risk Stratification in Prostate Cancer?
January 13th 2025Employing baseline MRI and clinical data, an emerging deep learning model was 32 percent more likely to predict the progression of low-risk prostate cancer (PCa) to clinically significant prostate cancer (csPCa), according to new research.
